Abstract:Introduction Emerging evidence has suggested that inherited factors are also involved in lung cancer development. However, most studies focused on well-elucidated cancer predisposition genes, the majority of which are tumor suppressor genes. The profile of germline mutations in oncogenic driver genes remains unrevealed, which might also provide potential clinical implications for lung cancer management. Methods Sequencing data from 36,813 unselected lung cancer patients who underwent somatic mutation profiling were retrospectively reviewed. All recruited patients had matched white blood cell samples sequenced in parallel using a capture-based panel including eight key lung cancer driver genes ( epidermal growth factor receptor ( EGFR), anaplastic lymphoma kinase (ALK), MET proto-oncogene, receptor tyrosine kinase (MET), Kirsten rat sarcoma viral oncogene homolog (KRAS) , Erb-B2 receptor tyrosine kinase 2(ERBB2), ROS proto-oncogene 1, receptor tyrosine kinase (ROS1), ret proto-oncogene (RET) , and B-Raf proto-oncogene, serine/threonine kinase ( BRAF) ). Likely pathogenic/pathogenic (LP/P) variants were called according to the classification criteria of the American College of Medical Genetics and Genomics. Variants of uncertain significance (VUS) located in the kinase domains of driver genes and occurring recurrently (n ≥3) were also included for further analyses. Results Seven different LP/P variants in EGFR , MET , or RET were identified in 0.03% of lung cancer patients (n = 14) and 25 different VUS in the kinase domains of seven driver genes (except KRAS ) were found with a prevalence of 0.3% (n = 117).Collectively, germline mutations were most frequently seen in ROS1 (n = 31, 0.084%), followed by MET (n = 23, 0.062%), EGFR (n = 22, 0.06%), ALK (n = 22, 0.06%) and RET (n = 17, 0.046%). LP/P variants and VUS fell the most commonly in EGFR (n = 10, 72%) and ROS1 (n = 31, 26%), respectively. Of the 10 patients with EGFR LP/P germline mutation, 70% also acquired somatic EGFR driver mutation exon21 p.L858R or exon19 deletion at baseline; while the three patients with pathogenic germline RET mutation displayed distinct baseline somatic profiles of rare EGFR mutation or KRAS exon2 p.G12C. We discovered 11 germline mutations that also occurred somatically, including four LP/P variants and seven VUS. Conclusion We present the first study to systemically characterize the germline mutation in oncogenic driver genes in a large cohort of unselected patients with lung cancers.

Germline variation networks in the PI3K/AKT pathway corresponding to familial high-incidence lung cancer pedigrees

Data from Cumulative Effect of Multiple Loci on Genetic Susceptibility to Familial Lung Cancer

Germline EGFR mutations and familial lung cancer

Genome-wide Association Study of Familial Lung Cancer.

Genetic Variations in Cancer-Related Significantly Mutated Genes and Lung Cancer Susceptibility.

Fine Mapping Of Chromosome 6q23-25 Region In Familial Lung Cancer Families Reveals Rgs17 As A Likely Candidate Gene

Candidate lung tumor susceptibility genes identified through whole-genome association analyses in inbred mice.

Supplementary Tables 1-7 from Cumulative Effect of Multiple Loci on Genetic Susceptibility to Familial Lung Cancer

Identification of the Unique Clinical and Genetic Features of Chinese Lung Cancer Patients With EGFR Germline Mutations in a Large-Scale Retrospective Study

Pedigree analysis of the EGFR p.V1010M germline mutation in a family with a family history of non-small-cell lung cancer

Rare germline deleterious variants increase susceptibility for lung cancer

Multiple Germline Events Contribute to Cancer Development in Patients with Li-Fraumeni Syndrome

Clinical and genetic characterization of cancer patients with multiple germline variants.

A Large-Scale Exome-Wide Association Study Identifies Novel Germline Mutations in Lung Cancer

Impact of genomic and epigenomic alterations of multigene on a multicancer pedigree

The Unique Genetic Mutation Characteristics Based on Large Panel Next-Generation Sequencing (NGS) Detection in Multiple Primary Lung Cancers (MPLC) Patients

Pathogenic germline variants in BRCA1 and TP53 increase lung cancer risk in Chinese

The pathogenic germline ETV4 P433L mutation identified in multiple primary lung cancer affect tumor stem-like property by Wnt/β-catenin pathway

Profiling Oncogenic Germline Mutations in Unselected Chinese Lung Cancer Patients

Co-occurrence of germline pathogenic variants in Chinese patients with solid tumors.

Potential genetic modifiers for somatic EGFR mutation in lung cancer: a meta-analysis and literature review